The DOI matches its Crossref record.
Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer.
Abstract
Twenty-six patients with advanced cancer refractory to standard therapy were treated with recombinant human tumor necrosis factor (rTNF) in a study aimed at determining the toxicity and tolerance of rTNF and at seeking evidence of antitumor activity. The study design involved two treatments per week for 4 weeks with alternating subcutaneous and intravenous (IV) administration, and weekly dose escalation through four levels in each patient. The dose range was 1 to 200 micrograms/m2 for IV bolus injection, and 5 to 250 micrograms/m2 for subcutaneous injection. Thirteen patients completed the full course. Early discontinuation of treatment was related to rTNF toxicity in seven cases. The major side effects were rigors, fever, headache, fatigue, and hypotension. Acute changes in granulocyte, lymphocyte, and monocyte counts, changes in serum zinc levels and plasma cortisol levels consistent with an acute phase response, and inflammation at the site of subcutaneous injection were also seen. At doses of 125 to 250 micrograms/m2, inflammation at the subcutaneous injection site was unacceptably severe. Minor changes were seen in hemostatic parameters. Hypotension was corrected by fluid administration and did not require treatment with vasopressors. Initial serum concentrations of rTNF were measured at five minutes after IV administration and were found to range from 2.5 ng/mL after a dose of 35 micrograms/m2 to 80 ng/mL after a dose of 200 micrograms/m2. The half-life of rTNF in the blood was 20 minutes. A decrease in lymph node size was observed in a patient with B cell lymphoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Interleukin-1 and Its Biologically Related Cytokines
Dinarello, C. A. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60642-2 · Cited by 1,151
Okusawa, S., Gelfand, J. A., Ikejima, T., Connolly, R. J., & Dinarello, C. A. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113431 · Cited by 983
Balkwill, F. R., & Burke, F. (1989) · Immunology Today · doi:10.1016/0167-5699(89)90085-6 · Cited by 783
The systemic inflammatory response syndrome
Meeran, H., & Messent, M. (2001) · Trauma · doi:10.1177/146040860100300203 · Cited by 425
Anticytokine Strategies in the Treatment of the Systemic Inflammatory Response Syndrome
Dinarello, C. A. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500140081040 · Cited by 405
Metadata
- Authors
- Chapman, P. B., Lester, T. J., Casper, E. S., Gabrilove, J. L., Wong, G. Y., Kempin, S. J., Gold, P. J., Welt, S., Warren, R. S., & Starnes, H. F.
- Venue
- Journal of Clinical Oncology
- Published
- 1987-12
- Volume
- 5
- Issue
- 12
- Pages
- 1942-1951
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1731514419
- Cited by
- 214
- References
- 0
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. https://app.cochat.ai/papers/10.1200/jco.1987.5.12.1942
- The paper
- Chapman, P. B., Lester, T. J., Casper, E. S., Gabrilove, J. L., Wong, G. Y., Kempin, S. J., Gold, P. J., Welt, S., Warren, R. S., & Starnes, H. F. (1987). Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1987.5.12.1942
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.